Asia-Pacific Anti-inflammatory Therapeutics Market 2014-2020

1
Anti-inflammatory Therapeutics Asia-Pacific Market
Research Report 2014-2020
Published Date 30-Jun-2015
No. Pages 130
2
Report Description
The Asia-Pacific anti-inflammatory therapeutics
market is expected to grow at a CAGR of 8.6 over
the forecast period, owing to the rising
healthcare expenditure, disposable income of
individuals, increasing popularity of biologics
and better healthcare access. Increase in the
number of autoimmune and respiratory diseases,
new drugs in development pipeline and increased
usage of OTC NSAIDs are the major factors driving
the Asia-Pacific anti-inflammatory market.
Moreover, increasing awareness of
anti-inflammatory biologics and favorable
government initiatives in the Asia-Pacific region
are expected to drive the market during the
analysis period. Factors, such as side effects of
anti-inflammatory drugs and uncertain patent
legislations, i.e., compulsory licensing in India
would continue to impede the market growth. The
Asia-Pacific anti-inflammatory therapeutics
market is segmented on the basis of indication,
drug class and geography.
3
Report Description
Among indications, arthritis was the dominant
segment accounting for 41.3 of the APAC
anti-inflammatory therapeutics market in 2014 and
holds potential for growth during the forecast
period. Anti-inflammatory biologics are the most
preferred drugs for treatment of arthritis.  On
the basis of drug class, the market is segmented
into anti-inflammatory biologics, non-steroidal
anti-inflammatory drugs (NSAIDs) and
corticosteroids. Anti-inflammatory biologics
holds the largest share among drug classes
accounting for around 50 share of the
Asia-Pacific anti-inflammatory therapeutics
market, and is expected to grow rapidly during
the forecast period. Geographically, the market
is segmented into six countries namely Japan,
China, India, Australia, South Korea, Indonesia
and others. 
4
Report Description
Among these countries, Japan holds the largest
share in the Asia-Pacific anti-inflammatory
therapeutics market however, China is expected
to exhibit the fastest growth during the forecast
period. In 2014, Novartis got marketing
approval for the drug Cosentyx (secukinumab) in
Japan for the treatment of psoriatic arthritis.
The company has filed new patents to overcome the
issues of patent expiries of their existing drugs
and to gain a prominent market share. The key
companies profiled in this report are Pfizer,
Inc., AbbVie, Inc., Johnson Johnson,
GlaxoSmithKline plc, Merck CO., Inc., Novartis
AG, F. Hoffmann-La Roche AG, Eli Lily and
Company, AstraZeneca PLC and Amgen.
5
Key Market Benefits

• The report provides a quantitative analysis of
  the current market and estimations during
  20142020 that assist in identifying and
  capitalizing on the prevailing market
  opportunities
• Exhaustive analysis of the Asia-Pacific
  anti-inflammatory therapeutics market by product
  type helps in understanding the types of
  therapeutics and their categories that are
  currently being used to gain prominence in future
• Competitive intelligence of leading manufacturers
  and distributors of anti-inflammatory
  therapeutics helps in understanding the
  competitive scenario across the geographies
• Comprehensive analysis of factors that drive and
  restrict the growth of the Asia-Pacific
  anti-inflammatory therapeutics market has been
  provided

6
Key Market Segments
7
Market - By Country
8
Table of Content
Chapter 1    Introduction Chapter 2    Executive
Summary Chapter 3    Market Overview Chapter
4 Asia-pacific Anti-inflammatory Therapeutics
Market By Indication Chapter 5  Asia-pacific
Anti-inflammatory Therapeutics Market By Drug
Class Chapter 6  Asia-pacific Anti-inflammatory
Therapeutics Market By Country Chapter 7  
 Company Profiles
9
FOR MORE DETAILS
Visit us at
http//www.apacmarket.com/top-market/anti-inflamma
tory-therapeutics-market
Stay With Us
TELEPHONE [phone]
EMAIL  help_at_apacmarket.com